Search Results for 'rituximab'
rituximab published presentations and documents on DocSlides.
Patients with total IgG <400 mg/dL while receiving rituximab should
by ivy
NOT. receive IgG replacement therapy. . AAIFNC F...
Carfilzomib , Rituximab and Dexamethasone (
by mindeeli
CaRD. ) Is Highly . Active and . Offers a Neuropat...
Update on Follicular Lymphoma:
by alexa-scheidler
Contemporary Treatment Strategies and Optimal Seq...
Chronic lymphocytic leukemia,
by natalia-silvester
New agents timing?. Agne Paner, MD. Assistant pro...
227 EMEA 2005 Since all the treatment regimens used so far have only
by priscilla
Zevalin, supplied as kit for radiopharmaceutical p...
rials as treatment options for eligible patients
by elysha
Page
1
of
13
Note
:
Consider
C
linical
T
.
Wa...
Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL?
by mitsue-stanley
Bertrand Coiffier. Service d. ’. Hématologie. ...
Updates in Lymphoma From Recent Congresses
by lindy-dunigan
Therapeutic Targets in CLL. Venetoclax in Patient...
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
by conchita-marotz
ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu....
Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)
by ellena-manuel
Swiss Group for Clinical Cancer Research (SAKK). ...
A Closer Look at Pemphigus Vulgaris: Clinical Challenges and
by celsa-spraggs
Emerging Treatments . Description of Program. Thi...
Please note, these are the actual video-recorded proceeding
by luanne-stotts
Moderator. Neil Love, MD. Mollie Moran, MSN, CNP,...
Integration of Novel Therapies in WM and CLL : When and How
by giovanna-bartolotta
Neil E Kay, M.D.. October 2014. Mayo Team. Deb Bo...
Update on Follicular Lymphoma:
by tatiana-dople
Contemporary Treatment Strategies and Optimal Seq...
Dr. Gilles Salles Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma
by isabella2
Dr. Gilles SALLES. Chief . of. . the. . Lymphoma...
In the name of god brief review on
by SugarAndSpice
nhl. Presenting by . F.Malek. M.D. Assistant Prof...
Module 3: Chronic Lymphocytic Leukemia
by CottonTails
Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . ...
BC Cancer Protocol Summary LYCHOPRMTXPage of
by melody
Activated: 1 Jun 2014 Revised: Mar 2022tests rev...
AuthorsAcceptedManuscriptCryoglobulinemicvasculitisandskinulcersOurth
by danya
www.elsevier.com/locate/semarthrit
Our therapeutic...
ContentslistsavailableatBloodReviewsjournalhomepagewwwelseviercoml
by oconnor
Diagnosisandtreatmentofautoimmunehemolyticanemiain...
Sartorius Stedim Biotech have developed a suite of binding assays using the
by harper
iQue. ®. Screener PLUS (. IntelliCyt. ). The . i...
Translating the biology of diffuse large B-cell lymphoma into treatment
by callie
Prof. . Alexey V. Danilov, MD, PhD,. 1. Dr. Massi...
Recent developments in the treatment of DLBCL
by payton
Prof. Georg Lenz, MD. Department of Haematology, O...
Drug Treatment of Hematopoietic Malignancy
by mitsue-stanley
Munir Gharaibeh, MD, PhD, MHPE. Department of Pha...
RituximabinIndolentLymphomasTarekSousouandJonathanFriedberg
by kittie-lecroy
Indolentnon-Hodgkinlymphoma(NHL)comprisesagroupofi...
New Perspectives in Treatment Strategies for Follicular Lymphoma
by olivia-moreira
Introduction. Standard Frontline Therapy for FL. ...
Indolent Lymphomas Dr. Melissa Toupin
by liane-varnes
The Ottawa Hospital. What does indolent mean?. Sl...
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...